Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.

  • March 4, 2026

  • 2 min

Share

Original Source(s)

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

  • March 4, 2026

Related Content

Correction: Laparoscopic and open feeding jejunostomy in upper gastrointestinal pathology: a single-centre cohort study

Clear Liquids, Safer Procedures—Lessons From the OCULUS Trial

Probiotics to Prevent Necrotizing Enterocolitis in Extremely Preterm Infants in a Neonatal Care Setting